[Importance of adrenoceptor blockers and alpha reductase inhibitors :  Monotherapy for treatment of benign prostate syndrome].
Medicinal treatment is the primary conservative treatment option for patients with moderate to severe lower urinary tract symptoms (LUTS). Monotherapy with alpha-blockers may be a suitable option for patients with a low risk of progression and with moderate to severe LUTS due to the rapid onset of action. However, alpha-blockers do not have any impact on disease progression and 5-alpha-reductase inhibitors (5-ARIs) are not recommended as initial monotherapy due to a slow onset of action. In the medium and long term 5-ARIs have been shown to have a positive effect on symptoms and the maximum flow rate and are also the only substance group to have a positive effect on disease progression. The positive effects of 5-ARIs on prevention of benign prostate syndrome are based on scientific findings but the use is not yet recommended in any guidelines.
Urologische Klinik und Poliklinik, Klinikum der Universität München-Großhadern, Marchioninistrasse 15, Munich, Germany. Frank.Strittmatter@med.uni-muenchen.de
F
F
Strittmatter
S
S
Madersbacher
C G
CG
Stief
C
C
Gratzke
D058891:5-alpha Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D019983:Guideline Adherence; D006801:Humans; D008134:Long-Term Care; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000187:drug effects; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D001748:Urinary Bladder Neck Obstruction / Q000175:diagnosis / Q000188:drug therapy; D014563:Urodynamics / Q000187:drug effects
D058891:5-alpha Reductase Inhibitors; D058668:Adrenergic alpha-1 Receptor Antagonists